Our Pricing

Mounjaro All Doses Available UK — Complete Stock Across All Strengths

Published on: June 03, 2026

Finding mounjaro all doses available uk can be challenging during ongoing supply constraints, but Cured Pharmacy maintains complete stock across all strengths from 2.5mg starter pens to 15mg maintenance doses. Our UK-registered clinical team provides free consultations under three minutes, with transparent pricing from £135.00 and discreet next-day delivery across the United Kingdom.

Why Mounjaro Dose Availability Matters for Your Weight Loss Journey

Mounjaro (tirzepatide) requires careful dose escalation to minimise gastrointestinal side effects whilst optimising weight loss outcomes [1]. The licensed titration schedule begins at 2.5mg weekly for four weeks, increasing to 5mg, then potentially to 7.5mg, 10mg, 12.5mg, or 15mg based on individual response and tolerability. Interruptions to this schedule due to stock shortages can compromise treatment efficacy and increase the risk of side effects when restarting.

Clinical trials including SURMOUNT-1 demonstrated that patients following the complete dose escalation protocol achieved average weight reductions of 20.9% at the 15mg maintenance dose over 72 weeks [1]. Missing doses or inconsistent supply can disrupt the metabolic adaptations that drive these outcomes, making reliable access to all strengths essential for successful long-term weight management.

At Cured Pharmacy, we maintain stock across all seven Mounjaro strengths (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg KwikPens), ensuring continuity of care throughout your treatment journey. Our superintendent pharmacist Tarun Kumar oversees procurement directly with UK-licensed wholesalers, prioritising consistent availability for existing patients whilst accepting new consultations.

How Mounjaro Works: Dual GIP/GLP-1 Receptor Activation

Tirzepatide represents the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for weight management [2]. This dual mechanism distinguishes Mounjaro from single-pathway GLP-1 treatments, activating two complementary hormonal systems that regulate appetite, gastric emptying, and glucose metabolism.

The GLP-1 component reduces appetite through hypothalamic pathways and slows gastric emptying, whilst the GIP receptor activation enhances insulin secretion and may improve fat metabolism [2]. This synergistic action produces greater weight loss than GLP-1 monotherapy in head-to-head trials, with the 15mg dose achieving 5.5kg greater reduction than semaglutide 1mg over 40 weeks in the SURPASS-2 study [3].

Peak plasma concentrations occur approximately 24 hours post-injection, with a half-life of five days enabling once-weekly administration [2]. The medication is administered subcutaneously in the abdomen, thigh, or upper arm using the pre-filled KwikPen device, which requires no dose calculation or manual preparation.

Expected Timeline for Weight Loss Results

Most patients begin noticing appetite reduction within the first week of treatment, though measurable weight loss typically becomes apparent after 4-8 weeks at therapeutic doses [1]. The dose escalation phase (first 8-20 weeks depending on target dose) balances efficacy against tolerability, with maximum weight loss generally occurring between weeks 60-72 of continuous treatment. Clinical trials showed that patients reaching the 15mg maintenance dose lost an average of 21kg from baseline by week 72, compared to 3kg in placebo groups [1].

Mounjaro Dosing Schedule and Strength Selection

The MHRA-approved titration protocol begins with 2.5mg once weekly for four weeks, followed by an increase to 5mg weekly. If additional weight loss is needed and the 5mg dose is well-tolerated, your prescriber may increase the dose in 2.5mg increments at four-week intervals, up to a maximum of 15mg weekly [4]. Not all patients require the highest dose—clinical response and side effect profile guide individualised dose selection.

Each KwikPen contains four weekly doses of a single strength, eliminating the need for dose adjustment or cartridge changes. The pen features a simple twist-and-inject mechanism with audible clicks confirming dose delivery. Used pens should be disposed of in a sharps container, available free from most UK pharmacies or local authority waste services.

Patients who miss a dose should administer it within four days of the scheduled injection, then resume the regular weekly schedule. If more than four days have passed, skip the missed dose and continue with the next scheduled injection to avoid overlapping doses [4]. Consistency in injection timing optimises steady-state drug levels and reduces breakthrough hunger between doses.

When to Consider Dose Increases

Your UK prescriber will assess whether dose escalation is appropriate based on weight loss progress (typically targeting 5% reduction within 12 weeks), tolerability of current dose, and absence of contraindications. Some patients achieve their goals at 5mg or 7.5mg and may not require higher doses, whilst others benefit from titration to 12.5mg or 15mg for optimal results. Regular clinical reviews every 8-12 weeks ensure your treatment plan adapts to your individual response.

Mounjaro All Doses Available UK: Comparing Weight Loss Treatments

The UK weight management landscape includes several prescription options, each with distinct mechanisms, dosing schedules, and clinical evidence profiles. Injectable GLP-1 receptor agonists—including Mounjaro, Wegovy, and Saxenda—demonstrate superior efficacy compared to oral treatments like Orlistat or Mysimba in head-to-head trials [5].

Wegovy (semaglutide) activates GLP-1 receptors exclusively and requires weekly injections, producing average weight loss of 15% over 68 weeks in the STEP-1 trial [5]. Saxenda (liraglutide) also targets GLP-1 receptors but requires daily injections due to its shorter half-life, achieving approximately 8% weight reduction in clinical studies. Oral options like Orlistat work through fat absorption inhibition rather than appetite regulation, producing more modest results of 3-5% weight loss when combined with dietary modification.

Mounjaro's dual GIP/GLP-1 mechanism produces statistically greater weight loss than semaglutide in comparative trials, though individual response varies [3]. Treatment selection depends on multiple factors including baseline BMI, previous weight loss attempts, injection frequency preference, cost considerations, and medical history. All injectable treatments require prescription-only access following clinical assessment by a UK-registered prescriber.

Managing Side Effects and Optimising Mounjaro Tolerance

Gastrointestinal effects represent the most common side effects during Mounjaro treatment, particularly during dose escalation phases. Nausea occurs in approximately 25-30% of patients, typically mild-to-moderate and diminishing after 4-8 weeks at each new dose [1]. Diarrhoea, constipation, abdominal discomfort, and reduced appetite follow similar patterns, generally resolving as the body adapts to treatment.

Practical strategies to minimise GI side effects include eating smaller, more frequent meals rather than large portions, avoiding high-fat or heavily spiced foods, staying well-hydrated, and taking the injection at a consistent time when you can rest if needed. If nausea persists, your prescriber may recommend remaining at your current dose for an additional 4-8 weeks before attempting further escalation, or prescribing anti-emetic medication for short-term symptom management.

Rare but serious risks include pancreatitis (discontinue immediately if severe abdominal pain occurs), gallbladder disease, and potential thyroid C-cell tumours observed in rodent studies [4]. Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will review your complete medical history during consultation to ensure Mounjaro is clinically appropriate and safe for your individual circumstances.

When to Contact Your Prescriber

Seek medical advice if you experience severe persistent abdominal pain (potentially indicating pancreatitis), signs of allergic reaction including facial swelling or difficulty breathing, persistent vomiting preventing fluid intake, symptoms of gallstones including right upper abdominal pain and jaundice, or visual changes. Regular follow-up consultations every 8-12 weeks allow your clinical team to monitor progress, adjust doses appropriately, and address any emerging concerns before they become problematic.

Ordering Mounjaro from Cured Pharmacy: Clinical Process and Delivery

Accessing Mounjaro through Cured Pharmacy begins with a free online consultation taking under three minutes to complete. Our clinical questionnaire covers your medical history, current medications, weight loss goals, previous treatment attempts, and relevant health conditions. A UK-registered prescriber reviews your assessment within hours, typically the same working day for applications submitted before 3pm.

If Mounjaro is deemed clinically appropriate and safe based on your individual profile, the prescriber issues an electronic prescription transmitted directly to our dispensary. Our GPhC-registered pharmacy team (registration number 9012511) dispenses genuine UK-licensed Mounjaro KwikPens, with superintendent pharmacist Tarun Kumar (GPhC 2233073) overseeing all clinical governance and medication safety protocols.

Orders placed before 3pm Monday-Friday qualify for next-day delivery via tracked courier service in discreet, unmarked packaging with no external indication of contents. All Mounjaro doses from 2.5mg through 15mg are currently in stock, with automatic prescription renewals available for established patients to ensure continuity of treatment. Pricing starts from £124.99 depending on prescribed strength, with transparent costs displayed before consultation—no hidden fees or unexpected charges at checkout.

Ongoing Clinical Support and Treatment Reviews

Cured Pharmacy provides continuous clinical support throughout your weight loss journey, not just initial prescription access. Our clinical team remains available via phone (+44 116 4646009) or secure messaging for questions about side effects, dose timing, injection technique, or general treatment concerns. Scheduled reviews every 12 weeks assess your progress, evaluate whether dose adjustments are warranted, and ensure Mounjaro remains the optimal treatment choice as your weight and health status evolve.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
4. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/14269 [accessed 13 August 2026]
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine and may not be suitable for everyone. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, dietary modification, and physical activity levels.